3) consists of carboxypeptidase NI (CNi) and carboxypeptidase N2 (CNi); these two enzymes can be differentiated by their activities towards hippuryl-L-arginine and hippuryl-L-lysine, respectively. A Spectrophotometric assay for both carboxypeptidases in human serum is described and the biochemical behaviour of these enzymes investigated. The pH optima are found to be 8.4 for CNi and CN 2 . The Michaelis-Menten constants are: CNi 4.59 ± 0.03 mmol/i; CN 2 37.26 ± 3.49 mmol/1. CN 2 can be inhibited by EDTA (76%), dimercaprolum (97%) and phenanthroline (98%). Diisopropylfluorophosphate has no influence on both enzymes. Elevated haemoglobin only interferes with CNi measurements, and high bilirubin concentfations slightly alter the activity of both enzymes. High CNi activities were found in sera of patients with sarcoidosis, and elevated CN 2 activities were found in lung cancer.
Introduction
An enzyme capable of rapidly releasing carboxylterminal lysine and äfginine from peptides has been found in the bovine pancreas (1) . This enzyme was named carboxypeptidase B (EC 3.4.17.3) or basic carboxypeptidase and was also purified (2) and characterized (3, 4) . Other tissues also have carboxypeptidase B activity (5, 6) . In human plasma, carboxy- peptidase B-like activity was found, which differs from the isolated pancreas enzyme in molecular weight, the velöcity of hydrolysis of lysine-containing Substrates compared to arginine-containing substrätes, and Inhibition patterns (7) . Additionally, it inactivates the nonapeptide bradykinin by removing the C-terminal arginine; therefore it is also called kininase I. In human plasma, carboxypeptidase N has a molecular weight of 280000. Left Standing it dissociates to subunits of 45000 and 90000 (8) . The plasma enzyme activity was low in some diseases of the liver, which indicate that the liver and not the pancreas is the site of enzyme synthesis. The physiological and pathophysiological role of this aminopeptidase in human body fluid has not yet been thoroughly clarified. One reason for the lack of interest in this enzyme may be that the known methods are not routinely practiced in clinical laboratories. Therefore we developed a simple spectrophotometric method for the determination of this carboxypeptidase. This assay is based on the estimation of hippuric acid formed by carboxypeptidase N from two synthetic Substrates.
Carboxypeptidase NI (CNi) cleaves the synthetic Substrate hippuryl-L-arginine, while carboxypeptidase N2 (CN2) is used for Splitting the hippuryl-L-lysine. After biochemical characterisation of both enzymes, this method was applied to a large number of untreated sera in various lung diseases.
Materials and Methods

Reagents
Hippuric acid, hippuryl-L-arginine, hippuryl-L-lysine, diisopropylfluorophosphate, ethylenediaminetetra-acetic acid (EDTA), dimercaprolum, phenanthroline, bilirubin and haemoglobin were purchased from Sigma, Munich.
AH other chemicals of high purity were obtained from Merck, Darmstadt. Test tubes were from Sarstedt, Stuttgart. In all assays distilled and deionized water was used.
0.05 mol/1 hippuryl-L-arginine solution, molecular weight 335.4, was prepared by dissolving 167.7 mg hippuryl-L-arginine in 10 ml of 0.5 mol/1 potassium phosphate buffer, pH 8.4; 0.1 mol/1 hippuryl-L-lysine solution, molecular weight 307.3, was mixed by dissolving 307.3 mg hippuryl-L-lysine also in 10 ml of the same buffer. The buffer was prepared by mixing solution A (containing 87 g/l (0.5 mol/1) K 2 HPO 4 and 43.8 g/l (0.75 mol/1) NaCl) and solution B (containing 68.0 g/l (0.5 mol/1) KH 2 PO 4 and 43.8 g/l (0.75 mol/1) NaCl). A sufficieiit quantity of solution B was added to 100ml of solution A to achieve a pH of 8.4 at 20 °C.
The buffer was stored at 4 °C, which caused some precipitation, but the precipitate redissolved at 20 °C.
Serum samples
Blood was collected from healthy controls and from patients with various diseases under the following conditions: Arm venipuncture was performed at 7.30 a. m. after fasting for 2 h and bed rest, with no administration of drugs during the preceding 24 h. The healthy donors had l h h bed rest. The blood was allowed to clot in a 10ml polypropylene test tube. Blood was centrifugated for 10 min at 1200 g in a Heraeus cryofuge at 4 °C, and the supernatant was carefully removed and stored at -20°C until assay.
Incubation procedure 50 μΐ serum for measurement of CN,, or 25 μΐ serum for CN 2 , was added to 200 μΐ of Substrate buffer solution containing hippuryl-L-arginine or hippuryl-L-lysine in duplicated 4 ml polypropylene test tubes, tightly covered, vortexed for 15 s and incubated for 60 min at 37 °C in a temperature controlled shaker water bath. The enzymatic reaction was stopped by addition of 250 μί of l mol/1 HC1 solution and vortexed for 15 s. The blanks were similary treated except that after addition of serum the enzymatic reaction was stopped at once by 250 μΐ of l mol/1 HC1 before incubation.
All samples were removed from the water bath and placed in crushed ice for 5min. Afterwards, 1500μΙ ethyl acetate were added, vortexed for 30s and centrifuged for 10min at 4000g. l ml of the upper layer (ethyl acatate) was pipetted into a 4 ml test tube and placed in a boiling water bath for 45-60 min to evaporate the ethyl acetate thoroughly. 3 ml of l mol/1 NaCl solution was added to each tube and vortexed for 30 s. All samples were placed in a water bath at 70 °C for 5 min to redissolve all the residual hippuric acid, then vortexed for 30 s. After 15 min Standing at foom temperature, the absorbance of the hippuric acid was read in a l-cm rectangular cuvette at 228 nm in a Hitachi precisiori spectralphotometer 100-40, with distilled deionized w ter s a blank.
As internal Standard serum, a pool serum of normal persons was used.
Calculation of catalytic activity l Unit (U) of carboxypeptidase N activity is defined s the amount of enzyme required to release l μηιοί hippuric acid per min at 37 °C under Standard assay conditions in l ml sefum (i. e., U/ml = kU/l = μτηοΐ/ml · min). Additionally, ro tine lab ratory parameters were evaluated frorri the same serum samples used for enzymatic measurements.
Results
Since samples are stored in crushed ice before incubation, there is a time lag before the incubation mixture attains 37 °C. For this reason the course of reaction of the carboxypeptidases did not achieve linearity until after 10^20 min, using hippuryl-L-argifiine or hippuryl-L-lysine s synthetic Substrates. The reaction was still linear up to 120 min ( fig. 1 ). In o f foutine assay we used an incubation time of 60 min, which clearly guarantees linearity.
The pKUdependence of CNi and CN 2 was investigated, using potassium phosphate buffer. In repeated assays CNi showed a small peak of activity at pH 8.4 ( fig. 2 ). For CNi a broad pH Optimum was found between 8.2 and 8.6. In s bsequent enzymatic reactions, we also used pH 8.4 for Linearity of the assay could also be proven by serum dilution ( fig. 3) . CN activity was plotted s dilution factor. The linear regression analysis gave (CNir ==? 0.99, CN 2 r = 0.98).
To iiivestigate the dependence of catalytic activity on the incubation temperat re, incubations were performed between -f 2 °C and +63~5C in a'heated water bath, CNi showed highest activity at 40 °C, CN 2 at 41°C<fig.5). The stability of CNi and CN2 was tested during st rage at -20 P C for up to 12 months. Only slight decreases of CNj (9.3%) and CN 2 (5.3%) were observed ( fig. 4) . Blocking agents were also tested (tab. 1). EDTA inhibits only CN 2 (76%) and shows no Inhibition of CN 2 could be nearly totally blocked by dimercaprolum (97%), but CNt was inhibited by only 54%. Similiar results were obtained for Inhibition by phenTab. L Inhibitor concentrations necessary to produce 50% Inhibition (Iso) of carboxypeptidase NI (CNi) and N 2 (CN 2 ) measured under Standard assay conditions described in the text. anthroline: CNi (64%), CN 2 (98%). Diisopropylfluorophosphate had no inhibitöry effect on CNi or CN 2 activity, but the curves suggest a sligbt activa? tion of both enzymes.
The interference of bilkubin and haemoglobin was also tested. Initially bilirubin redüced carboxypeptidase activity slightly. Only CNi activity was deĉ reäsed by additiön of haemoglobin.
For the precision of these methods see table 2.
We measured CNi an4 CN 2 in heaLthy controls and in patients with various Jung diseases (tab. 3). No positive correlatipn could be found in 47 normal subjects between cholesterol (CNn r = 0.04; CN 2 r = 0.08) and tfiglycerides (CNi: f = 0.01; CN 2 f = 0.10). Significantly elevated activities of CNi were found in sera of patients with safcöidosis (p < 0.0001) compared with thehealthy controls aind with lung cancer patients (p < 0.002). CN 2 was significäntly increased in patients with lung cancer (p < 0.0001) compared with cbrftrols and with saiv coidosis patients (p < 0.02).
Discussion
Our interest in carboxypeptidase was prompted by our studies of the angiotensin-I^converting enzyme in lung diseases. Angiotensm-I-converting enzyme was found to be elevated in sarcoidosis (9) and liver diseases (10) . Similar behaviour by other carboxypeptidases in human blood was expected. The method described here for the determination of and CN 2 activity in serum by spectrpphotomet- Clinical Chemistry is a special discipline of medicine which, due tö its close relationship both to medicine and to Chemistry, is of particular interest to the historian of science. This "History of Clinical Chemistry" is based on a modern outlook on the history of science. Since the investigation of the history of Clinical Chemistry is still in progress, the book is divided into eight separate contributiöns, writteh primarily by historiahs öf science, which together prövide a good coverage of the history of Clinical Chemistry in the nineteenth Century. The book is written entirely in English and will therefore appeal to an international readership. Each contribution is provided with numerous notes and referehces. Tab. 3. Carboxypeptidase NI and Na catalytic concentrations in serum of patients with lung diseases compared with heaithy controls. In sarcoidosis CNi was significantly elevated (p < 0.002) and CN2 was redüced (p < 0.02) compared with lung cancer. Previous reports showed that human serum CN could be separated by isoelectric focusing into two subunits (12) . The subunits of CN could also be distinguished by immunological methods (13) . It was speculated that CN consists of two species which were apparently isoenzymes (12).
With our method, which is derived from the spectrophotometric measurement of angiotensin-I^convert-ing enzyme (9), we also foutid differences in biochemical behaviour between CNi and CNz. The pH curve showed a broad pH Optimum when using hippuryl-L-lysine äs Substrate. The AT m -values indicate that the affinity of the enzyme activity to hippuryl-Larginine is greater than to hippuryl-L-lysine. Only CN 2 could be inhibited by EDTA, CNi was not influenced by this chelating agent. For comparison, the K m of carboxypeptidase B, which cleäves the same Substrates, is 0.21 x 10~3 mol/1 for hippuryl-L-arginine and 7.7 x l O" 3 mol/1 for hippüryl-L-lysine (11) . This shows that CNi removes the C terminal argiiiine faster than lysine. Pancreatic carböxypeptidase B acts in the same way, but the Inhibition patterns show differences between carboxypeptidase B and CN.
Previous studies, using hippuryl-L-lysine äs enzyme Substrate, describe normal values of carboxypeptidase N in pregnant women and in some patients with tumours. Redüced activity was found in patients with cirrhosis of the liver (14, 15) , which indicate that this enzyme may be synthesized in liver tissue. This could result in a decreased inactivation of bradykinin and other vasodilatating peptides in liver diseases. We measured CNi and CNa in patients with lung diseases and found high activities of CNi in sarcoidosis, and high activities of CN 2 in lung cancer compared with heaithy controls. Initial investigations indicate that the elevation of CNi in sarcoidosis is a better parameter of clinical activity than angiotensin-I-converting enzyme. Like angiotensin-I-converting enzyme, the source of CNi may be the epitheloid cells. There is some evidence that CN 2 is produced by malignant tumour cells.
